Reduced and oxidized polysaccharides and methods of use thereof

US10780171B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10780171-B2
Application numberUS-201615770937-A
CountryUS
Kind codeB2
Filing dateOct 26, 2016
Priority dateOct 26, 2015
Publication dateSep 22, 2020
Grant dateSep 22, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.

First claim

Opening claim text (preview).

What is claimed is: 1. A composition comprising a reduced polysaccharide, wherein said reduced polysaccharide comprises less than 2% of residual aldehydes; said reduced polysaccharide comprises ring opened monomeric subunits comprising alcohol moieties; and wherein said reduced polysaccharide is selected from the group consisting of reduced alginate, agarose, pullulan, scleroglucan, chitosan, elsinan, xanthan gum, mannose, gellan, levan, cellulose, hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, chondroitin sulfate E and β-d-glucans. 2. The composition of claim 1 , wherein said reduced polysaccharide is reduced alginate. 3. The composition of claim 2 , wherein said reduced alginate comprises algoxinol having the following structure: 4. The composition of claim 1 , wherein said composition further comprises a cross-linking agent attached to the reduced polysaccharide. 5. The composition of claim 4 , wherein said cross-linking agent is a click reagent. 6. A hydrogel comprising a plurality of reduced polysaccharides cross-linked to each other, wherein said hydrogel comprises a mesh size of 10 nm or less, wherein said reduced polysaccharides comprise less than 2% of residual aldehydes; said reduced polysaccharides comprise ring opened monomeric subunits comprising alcohol moieties; and wherein said reduced polysaccharides are selected from the group consisting of reduced alginate, agarose, pullulan, scleroglucan, chitosan, elsinan, xanthan gum, mannose, gellan, levan, cellulose, hyaluronic acid, chondroitin sulfate A, chondroitin sulfate C, chondroitin sulfate E and β-d-glucans. 7. The hydrogel of claim 6 , wherein said reduced polysaccharides comprising less than 2% of residual aldehydes are reduced alginate polymers produced by a method comprising the steps of: reacting an alginate with a diol specific oxidizing agent to produce an aldehyde containing oxidized alginate; and reacting said aldehyde containing oxidized alginate with a water soluble aldehyde specific reducing agent, thereby producing said reduced alginate polymers. 8. The hydrogel of claim 7 , wherein said diol specific oxidizing agent is sodium periodate and wherein said water soluble aldehyde specific reducing agent is ammonia borane. 9. The hydrogel of claim 6 , further comprising a therapeutic or diagnostic agent selected from the group consisting of a cell, a small molecule and a biologic. 10. The hydrogel of claim 6 , wherein said reduced polysaccharides comprise a cross-linking agent attached to the reduced polysaccharides. 11. An implantable or injectable device comprising the hydrogel of claim 6 . 12. A drug delivery composition comprising a lipid based nanoparticle encapsulating a therapeutic or diagnostic agent; and the hydrogel of claim 6 encapsulating said lipid based nanoparticle. 13. A method for treating a subject in need thereof, the method comprising administering to said subject an effective amount of a hydrogel of claim 6 , thereby treating said subject. 14. A method of treating chronic ischemia or enhancing engraftment of a transplanted tissue in a subject in need thereof, the method comprising administering to said subject an effective amount of a hydrogel of claim 6 , thereby treating said chronic ischemia or enhancing engraftment of said transplanted tissue in said subject. 15. The composition of claim 1 , wherein said reduced polysaccharide is produced by reacting a polysaccharide with a diol specific oxidizing agent, thereby producing a diol containing oxidized polysaccharide comprising 0.1% or more oxidation on a molar basis; followed by reacting said oxidized polysaccharide with a water soluble aldehyde specific reducing agent to produce said reduced polysaccharide. 16. The composition of claim 15 , wherein said aldehyde specific water soluble reducing agent is selected from the group consisting of sodium cyanoborohydride (NaCNBH 3 ); hydrogen gas (H 2 ) in the presence of a catalyst; ammonia borane (H 3 NBH 3 ); and a borane complex. 17. The composition of claim 16 , wherein said aldehyde specific water soluble reducing agent is ammonia borane. 18. The composition of claim 15 , wherein said diol specific oxidizing agent is sodium periodate. 19. The composition of claim 4 , wherein said cross-linking agent is attached to said reduced polysaccharide via a carboxylic moiety. 20. The composition of claim 5 , wherein said click reagent is selected from the group consisting of azide, dibenzocyclooctyne (DBCO), transcyclooctene, tetrazine and norbornene and variants thereof. 21. The hydrogel of claim 10 , wherein said cross-linking agent is a click reagent. 22. The hydrogel of claim 21 , wherein said click reagent is selected from the group consisting of azide, dibenzocyclooctyne, transcyclooctene, tetrazine and norbornene and variants thereof. 23. The hydrogel of claim 10 , wherein said cross-linking agent is attached to the reduced polysaccharides via a carboxylic moiety.

Assignees

Inventors

Classifications

  • Alginic acid; Derivatives thereof · CPC title

  • Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates · CPC title

  • Otologicals · CPC title

  • Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin · CPC title

  • Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10780171B2 cover?
The present invention is directed to reduced and highly oxidized polysaccharides, such as alginates, that are useful for encapsulating therapeutic or diagnostic agents, or lipid based nanoparticles, e.g., liposomes or virosomes, encapsulating therapeutic or diagnostic agents, prior to their delivery into a subject, as well as methods for making and using them.
Who is the assignee on this patent?
Harvard College
What technology area does this patent fall under?
Primary CPC classification C08B37/0084. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).